Theriva Biologics, Inc. financial data

Symbol
TOVX on NYSE
Location
Rockville, MD
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 131% % -53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45,892,668 shares 1549%
Common Stock, Shares, Outstanding 35,688,350 shares 1183%
Entity Public Float $3,900,000 USD -26%
Common Stock, Value, Issued $34,000 USD 1033%
Weighted Average Number of Shares Outstanding, Basic 12,140,697 shares 801%
Weighted Average Number of Shares Outstanding, Diluted 12,140,697 shares 801%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $8,604,000 USD -28%
General and Administrative Expense $15,447,000 USD 109%
Operating Income (Loss) $24,051,000 USD 8.7%
Nonoperating Income (Expense) $312,000 USD -55%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $23,739,000 USD 7.5%
Earnings Per Share, Basic -2.08 USD/shares 89%
Earnings Per Share, Diluted -2.08 USD/shares 89%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,056,000 USD 12%
Assets, Current $17,467,000 USD 7.3%
Property, Plant and Equipment, Net $222,000 USD -18%
Operating Lease, Right-of-Use Asset $803,000 USD -37%
Intangible Assets, Net (Excluding Goodwill) $19,619,000 USD 13%
Goodwill $0 USD -100%
Assets $38,239,000 USD 8.2%
Accounts Payable, Current $1,014,000 USD 18%
Employee-related Liabilities, Current $443,000 USD -61%
Accrued Liabilities, Current $6,276,000 USD 86%
Liabilities, Current $10,014,000 USD 32%
Operating Lease, Liability, Noncurrent $352,000 USD -60%
Liabilities $22,856,000 USD 40%
Accumulated Other Comprehensive Income (Loss), Net of Tax $755,000 USD
Retained Earnings (Accumulated Deficit) $358,710,000 USD -7.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $15,383,000 USD -19%
Liabilities and Equity $38,239,000 USD 8.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,756,000 USD 2.6%
Net Cash Provided by (Used in) Financing Activities $3,072,000 USD
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 35,717,159 shares 1171%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,591,000 USD 68%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,102,000 USD 12%
Deferred Tax Assets, Valuation Allowance $12,537,000 USD 11%
Deferred Tax Assets, Gross $17,984,000 USD 13%
Operating Lease, Liability $901,000 USD -36%
Lessee, Operating Lease, Liability, to be Paid $973,000 USD -40%
Property, Plant and Equipment, Gross $1,188,000 USD -1.4%
Operating Lease, Liability, Current $549,000 USD 1.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $368,000 USD -37%
Lessee, Operating Lease, Liability, to be Paid, Year One $605,000 USD -10%
Operating Lease, Weighted Average Discount Rate, Percent 0.0993 pure -4.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $72,000 USD -67%
Lessee, Operating Lease, Liability, to be Paid, Year Three $368,000 USD -37%
Deferred Tax Assets, Operating Loss Carryforwards $13,044,000 USD 34%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $26,000 USD -33%
Deferred Tax Assets, Net of Valuation Allowance $5,447,000 USD 18%